Industry veteran joins Auxilium Pharmaceuticals

Adrian Adams succeeds Armando Anido at the US firm

Auxilium Pharmaceuticals, a specialist biopharmaceutical company based in Malvern, PA, US, has appointed Adrian Adams as chief executive and president, effective immediately. Adams succeeds Armando Anido, who has agreed to step down and has resigned as a member of the Board. Adams will also succeed him on the Board.

Adams has more than 30 years of experience in the pharmaceutical industry, most recently serving as chairman and ceo of Neurologix, a biotechnology company engaged in the development of gene therapies for disorders of the brain and central nervous system. Prior to that, he was president and ceo of Inspire Pharmaceuticals, where he oversaw the development and commercialisation of prescription pharmaceutical products and led the company through a strategic acquisition by Merck & Co.

Before joining Inspire, Adams was president and ceo of Sepracor until its acquisition by Dainippon Sumitomo Pharma Co in 2010. Prior to this, he was president and ceo of Kos Pharmaceuticals from 2002 until the company was acquired by Abbott Laboratories in 2006.

Adams has also held general management and senior international and national marketing positions at Novartis, SmithKline Beecham and ICI (now part of AstraZeneca).

You may also like

Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Ingredients

Safe and accurate flow measurement for pharmaceutical production

Oval Gear (OG) meters from Titan Enterprises, fitted with a Namur sensor, provide consistent, accurate measurement across a wide range of liquids, from low-viscosity solvents to more viscous pharmaceutical ingredients
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Pharmaceutical

CellCarta and Leica Biosystems expand companion disgnostic development model partnership

Building on a successful CDx joint development model in China, the pair will aim to bring the end-to-end development framework to global customers to help their customers streamline the path to global CDx commercialisation
Manufacturing

ystral opens ATEX-compliant trial centre in Germany to expand customer process development capacity

The new facility, based in Ballrechten-Dottingen, will be able to handle flammable and explosive media testing across pharma, coatings and food applications, with remote livestream access and in-house particle size and viscosity analysis
Pharmaceutical

CelLBxHealth and AstraZeneca sign Master Services Agreement

The new contract establishes CelLBxHealth as a qualified service provider to AstraZeneca, allowing it to support drug discovery and development through CTC-powered analytics of clinical trial samples with its Parsortix platform
Microbiology

Nestlé Health Science and IdB partner to bring VOWST to Europe

Nestlé Health Science and IdB Holding have signed a licensing agreement to seek EMA approval for VOWST, the only FDA-approved oral live biotherapeutic for recurrent C. diff prevention
Subscribe now